Deferring systemic therapy may improve survival outcomes in carefully selected patients with metastatic renal cell carcinoma, new data suggest.

Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide, largely due to its high rate of recurrence after surgery. Even after complete tumor removal, microscopic ...

—Building on earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer, plus identify factors ...

Early research on proton craniospinal irradiation (pCSI) reported potential benefits for patients with LMD. Notably, the final analysis of a randomized phase 2 trial by Yang et al of 63 patients with ...